ArticleMedicine2026
Influence of obesity on the association between antinuclear antibodies and cognitive impairment: A nationwide population-based cross-sectional study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cognitive impairment is a significant health concern among older adults. Most cognitive disorders are challenging to treat due to their complex and often unclear causes. Emerging evidence suggests a possible association between antinuclear antibodies (ANA) and cognitive impairment, although this relationship remains debated. Obesity is associated with lower ANA titers and may influence ANA production. Therefore, the present study seeks to elucidate the impact of obesity status on the relationship between ANA and cognitive impairment. Data from the National Health and Nutrition Examination Survey (1999-2002), including 1050 participants, were analyzed. Multivariate logistic regression and interaction tests assessed the differences in ANA and cognitive impairment risk among participants within each subgroup. In this cross-sectional study, the association between ANA and cognitive impairment incidence varied between the obesity and nonobesity groups (OR: 0.24, 95% Cl: 0.07-0.82 vs OR: 2.15, 95% Cl: 1.19-3.89). A significant interaction was observed between ANA and obesity concerning cognitive impairment risk (P <.001). Obesity modifies the relationship between ANA and cognitive impairment and underscores the importance of metabolic context in interpreting immune-related biomarkers in cognitive impairment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.